EUVIMEDEUVIMED entdecken
Crossref

Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer

Qingzhu Liu iD, Shuai Qin, Shuyue Cai, Ling Qiu, Jianguo Lin iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Qingzhu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, Chi…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neuropilin-1, Positron-Emission Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Wuxi Municipal Health Commission, Jiangsu Province Capability Improvement Project through Science, Technology and Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a serious malignancy characterized by a lack of definitive biomarkers. Research has demonstrated that neuropilin-1 (NRP-1) is highly overexpressed in breast cancer, and its expression levels are strongly associated with the occurrence, development, and prognosis of tumors, thereby positioning NRP-1 as a promising target for the diagnosis and treatment of breast cancer, particularly for TNBC. Herein, NRP-1 was employed as a molecular marker to design and synthesize a PET/NIRF dual-modality molecular probe [18F]AmBF3-QS-1 for tumor localization and surgical navigation in TNBC. The nonradioactive NIRF probe AmBF3-QS-1 was synthesized through the click reaction (chemical purity >95%), and the radioactive probe [18F]AmBF3-QS-1 was synthesized via the one-step 18F-labeling method (radiochemical purity >95%, radiochemical yield >15%). The fluorescence imaging, flow cytometry, and cellular uptake studies in cancer cells with different NRP-1 expression levels were performed to verify the in vitro specificity of the probe. In vivo PET and NIRF imaging of MDA-MB-231 xenografts demonstrated excellent specificity of [18F]AmBF3-QS-1 for tumor uptake (8.41 ± 0.86%ID/mL, 9.67 ± 2.15 × 107 [p/sec/cm2/sr]/[μW/cm2]) with high-contrast ratios (5.91 ± 0.60, 2.80 ± 0.51). Additionally, ex vivo experiments showed that the probe AmBF3-QS-1 effectively guided tumor localization for precise resection and pathological examination. Collectively, the results demonstrate the potential of [18F]AmBF3-QS-1 as a promising dual-modality probe for noninvasive whole-body PET imaging to localize TNBC tumor as well as for NIRF imaging guidance to delineate tumor margins during surgical procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNeuropilin-1Positron-Emission TomographyHumansAnimalsFemaleMiceCell Line, TumorFluorine RadioisotopesMice, NudeRadiopharmaceuticalsMice, Inbred BALB COptical Imaging

Stichwörter der Autor:innen

18FPET/NIRFdual-modalityneuropilin-1triple-negative breast cancer

Substanzen

Neuropilin-1Fluorine RadioisotopesRadiopharmaceuticalsNRP1 protein, human

Autor:innen und Institutionen

  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.

ORCID-Profile: Qingzhu Liu, Jianguo Lin

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Wuxi Municipal Health Commission
  • Jiangsu Province Capability Improvement Project through Science, Technology and Education
  • Jiangsu Provincial Department of Science and Technology

Zitieren

APA

Liu, Q., Qin, S., Cai, S., Qiu, L., & Lin, J. (2025). Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00478

Vancouver

Liu Q, Qin S, Cai S, Qiu L, Lin J. Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00478

BibTeX
@article{Liu2025,
  author = {Liu, Qingzhu and Qin, Shuai and Cai, Shuyue and Qiu, Ling and Lin, Jianguo},
  title = {Neuropilin-1 Targeted Dual-Modality PET/NIRF Probe for the Noninvasive In Vivo Imaging of Triple-Negative Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00478}
}
Kostenlos starten →